Addition of highly sensitive troponin T and N-terminal pro-b-type natriuretic peptide to electrocardiography for detection of left ventricular hypertrophy: Results from the dallas heart study

Hypertension

Volumn 61, Issue 1, 2013, Pages 105-111

  Martinez Rumayor, Abelardo A ^a   De Lemos, James A ^a   Rohatgi, Anand K ^a   Ayers, Colby R ^b   Powell Wiley, Tiffany M ^a   Lakoski, Susan G ^a   Berry, Jarett D ^a   Khera, Amit ^a   Das, Sandeep R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

amino terminal B type natriuretic peptide; diagnostic performance; electrocardiographic Sokolow Lyon criteria; highly sensitive troponin T; left ventricular hypertrophy screening

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; TROPONIN T;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; DISEASE MARKER; ELECTROCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; SCREENING; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SOKOLOW LYON ELECTROCARDIOGRAPHIC CRITERIA;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; SENSITIVITY AND SPECIFICITY; TROPONIN T;

EID: 84871610235     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.195289     Document Type: Article

References (29)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566. (Pubitemid 20176696)
2. Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M, Solinas P, Gorini M, Maggioni AP; MAVI (MAssa Ventricolare sinistra nell'Ipertensione) Study Group. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol. 2001;38:1829-1835. (Pubitemid 33116551)
3. Verdecchia P, Porcellati C, Reboldi G, Gattobigio R, Borgioni C, Pearson TA, Ambrosio G. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation. 2001;104:2039-2044. (Pubitemid 33027044)
4. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfeld J, Yusuf S; Heart Outcomes Prevention Evaluation (HOPE) Investigators. Reduction of cardiovascular risk by regression of electro-cardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001;104:1615-1621. (Pubitemid 32947523)
5. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B; LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292:2343-2349. (Pubitemid 39491918)
6. Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004;110:1456-1462. (Pubitemid 39238023)
7. Pewsner D, Jüni P, Egger M, Battaglia M, Sundström J, Bachmann LM. Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ. 2007;335:711.
8. Cuspidi C, Meani S, Valerio C, Fusi V, Sala C, Zanchetti A. Left ventricular hypertrophy and cardiovascular risk stratifcation: impact and cost-effectiveness of echocardiography in recently diagnosed essential hypertensives. J Hypertens. 2006;24:1671-1677. (Pubitemid 44162471)
9. Choi SY, Lee JE, Jang EH, Kim MO, Baek H, Ki CS, Park SW, Kim DJ, Huh WS, Oh HY, Kim YG. Association between changes in N-terminal pro-brain natriuretic peptide levels and changes in left ventricular mass index in stable hemodialysis patients. Nephron Clin Pract. 2008;110:c93-100.
10. Wang AY, Lam CW, Wang M, Chan IH, Lui SF, Zhang Y, Sanderson JE. Diagnostic potential of serum biomarkers for left ventricular abnormalities in chronic peritoneal dialysis patients. Nephrol Dial Transplant. 2009;24:1962-1969.
11. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, Hashim I, Berry JD, Das SR, Morrow DA, McGuire DK. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304:2503-2512.
12. Okin PM, Jern S, Devereux RB, Kjeldsen SE, Dahlöf B; LIFE Study Group. Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients: the losartan intervention for endpoint (LIFE) reduction in hypertension study. Hypertension. 2000;35(1 Pt 1):13-18. (Pubitemid 30054230)
13. Victor RG, Haley RW, Willett DL, Peshock RM, Vaeth PC, Leonard D, Basit M, Cooper RS, Iannacchione VG, Visscher WA, Staab JM, Hobbs HH; Dallas Heart Study Investigators. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol. 2004;93: 1473-1480. (Pubitemid 38749202)
14. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J. 1949;37:161-186.
15. Molloy TJ, Okin PM, Devereux RB, Kligfeld P. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol. 1992;20:1180-1186.
16. Romhilt DW, Estes EH, Jr. A point-score system for the ECG diagnosis of left ventricular hypertrophy. Am Heart J. 1968;75:752-758.
17. Verdecchia P, Angeli F, Reboldi G, Carluccio E, Benemio G, Gattobigio R, Borgioni C, Bentivoglio M, Porcellati C, Ambrosio G. Improved cardiovascular risk stratifcation by a simple ECG index in hypertension. Am J Hypertens. 2003;16:646-652. (Pubitemid 36900587)
18. de Lemos JA, McGuire DK, Khera A, Das SR, Murphy SA, Omland T, Drazner MH. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study. Am Heart J. 2009;157:746-53.e2.
19. Drazner MH, Dries DL, Peshock RM, Cooper RS, Klassen C, Kazi F, Willett D, Victor RG. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: the Dallas Heart Study. Hypertension. 2005;46:124-129. (Pubitemid 40946502)
20. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol. 1995;25:1056-1062.
21. National Institutes of Health. Clinical guidelines on the identifcation, evaluation, and treatment of overweight and obesity in adults\the evidence report. Obes Res. 1998; 6:51S-209S.
22. Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007; 28:1462-1536.
23. Devereux RB, Liebson PR, Horan MJ. Recommendations concerning use of echocardiography in hypertension and general population research. Hypertension. 1987;9(2 Pt 2):II97-I104.
24. Centers for Medicare and Medicaid Services. Medicare Ambulatory Payment Classifcation 2011. https://www.cms.gov/HospitalOutpatientPPS. Accessed October 10, 2011.
25. Centers for Medicare and Medicaid Services. Clinical laboratory fee schedule database 2011. https://www.cms.gov/ClinicalLabFeeSched. Accessed October 10, 2011.
26. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, Levy D. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA. 2002;288:1252-1259. (Pubitemid 35001328)
27. Das SR, Alexander KP, Chen AY, Powell-Wiley TM, Diercks DB, Peterson ED, Roe MT, de Lemos JA. Impact of body weight and extreme obesity on the presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-Segment elevation myocardial infarction results from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol. 2011;58:2642-2650.
28. Myerson SG, Bellenger NG, Pennell DJ. Assessment of left ventricular mass by cardiovascular magnetic resonance. Hypertension. 2002;39:750-755. (Pubitemid 34252869)
29. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-1200. (Pubitemid 33015548)